Article ID Journal Published Year Pages File Type
8723429 Médecine des Maladies Métaboliques 2018 5 Pages PDF
Abstract
During the recent international meetings, were reported several trials evaluating the cardiovascular effects of the GLP-1 receptor agonists (GLP1-RA). Here we analyze and criticize the drug-agencies-required methodology used in these studies, which did not lead to equipoise between the arms with regard to risk factors. However, by taking together all these studies, we can conclude that GLP1-RA, when used at their maximal doses, are potent tools in secondary cardiovascular prevention, through leveraging on control of blood glucose and blood pressure.
Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Authors
, ,